3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 12 areas
0
News (30d)
Quiet
MAIA Biotechnology, Inc. is a company with 3 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| combined small cell lung carcinoma | 6-thio-2'-deoxyguanosine | Des.TrialAppr. |
| hepatocellular carcinoma | 6-thio-2¿-deoxyguanosine | Des.TrialAppr. |
| malignant glioma | 6-thio-2¿-deoxyguanosine | Des.TrialAppr. |
| non-small cell squamous lung carcinoma | 6-thio-2'-deoxyguanosine | Des.TrialAppr. |
| small cell lung carcinoma | 6-thio-2'-deoxyguanosine | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
27
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
27
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio